Survival analysis of triple negative breast cancer patients treated with Anthracycline based chemotherapy: A Retrospective Study from Central part of India

• Published in: IP Journal of Diagnostic Pathology and Oncology Vol. 5; no. 1; pp. 9 - 12
• Main Authors: Kumar Sachan, Dheerendra, Shrivastava, Abhishek, Sachan, Ruchita, Mandloi, Varsha
• Format: Journal Article
• Language: English
• Published: 28.02.2020
• ISSN: 2581-3714; 2581-3706
• DOI: 10.18231/j.jdpo.2020.002

Triple negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women. TNBC are biologically aggressive tumours, not benefited from hormonal or targeted therapy although some reports suggest that they respond well to chemotherapy. The aim of our study is was to assess the response of anthracyclines based adjuvant chemotherapy in triple negative breast cancer. This is was a retrospective study conducted on 100 post-operative patients, histopathologically proven ductal Carcinoma Breast, from January 2016 to March 2017 presenting to tertiary care centre. All patients were triple negative as assessed by immunohistochemistry and fluorescence in situ hybridization technique. Patients were planned for six cycles of Anthracycine based combination adjuvant chemotherapy. Data were analyzed by SPSS 20 and survival analysis was done. A total of 100 patients were included in this study. Out of these,18patients (18%) were defaulted after chemotherapy, 29 patients (29%) were lost during subsequent follow ups and 49 patients (49%) had disease free survival (DFS) and 4 patients (4%) survived with bone metastasis. The median survival was 18 months, disease free survival was 7.8 months and 3 year overall survival (OS) was 18.6 months. TNBC represent a challenge for the patients and the clinician due to its poor prognosis and fewer treatment options. The adjuvant Anthracycline -based combination chemotherapy predict improved long term outcomes for TNBC.